HCC is a major contributor to cancer-related mortality worldwide. Curative treatments are available for a minority of patients diagnosed at early stages; however, only a few multikinase inhibitors are available and are marginally effective in advanced cases, highlighting the need for novel therapeutic targets. One potential target is the protein arginine methyltransferase, which catalyzes various forms of arginine methylation and is often overexpressed in various cancers. However, the diverse expression patterns and clinical values of PRMTs in HCC remain unclear. In the present study, we evaluated the transcriptional expression of PRMTs in HCC cohorts using publicly available datasets. Our results revealed a significant association between PRMTs and prognosis in HCC patients with diverse clinical characteristics and backgrounds. This highlights the promising potential of PRMTs as prognostic biomarkers in patients with HCC. In particular, single-cell RNA (scRNA) sequencing analysis coupled with another human cohort study highlighted the pivotal role of PRMT1 in HCC progression, particularly in the context of Tex. Translating these findings into specific therapeutic decisions may address the unmet therapeutic needs of patients with HCC.
肝细胞癌是全球癌症相关死亡的主要原因。早期诊断的患者中仅有少数可获得根治性治疗；然而，对于晚期病例，目前仅有的几种多激酶抑制剂疗效有限，这凸显了对新治疗靶点的迫切需求。蛋白精氨酸甲基转移酶是一个潜在靶点，它能催化多种形式的精氨酸甲基化，并在多种癌症中过度表达。然而，PRMTs在肝细胞癌中的多样化表达模式及其临床价值尚不明确。本研究利用公开数据集评估了肝细胞癌队列中PRMTs的转录表达情况。结果显示，在不同临床特征和背景的肝细胞癌患者中，PRMTs与预后存在显著关联，这凸显了PRMTs作为肝细胞癌预后生物标志物的巨大潜力。特别是单细胞RNA测序分析结合另一项人类队列研究，揭示了PRMT1在肝细胞癌进展中的关键作用，尤其是在Tex背景下。将这些发现转化为具体的治疗决策，可能满足肝细胞癌患者尚未被满足的治疗需求。
肿瘤(癌症)患者之家